Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 5;11(1):159–167. doi: 10.3892/ol.2015.3870

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Ma et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 7. — Survivin-siRNA inhibited lymphangiogenesis and lung metastasis in vivo. (A) Representative images of the tumor sections examined by immunohistochemical staining for podoplanin, revealing the tumor vasculature (magnification, ×400). (B) Murine breast cancer 4T1 cells that were stably transfected with survivin-siRNA displayed significantly fewer pulmonary metastatic colonies than those cells in the UT and siRNAscr groups. (C) The expression levels of podoplanin and the mean vessel density within the tumors were reduced following stable injection of survivin-siRNA, compared with the UT and siRNAscr groups. Each bar represents the average vessel number for each group. All data are expressed as the mean ± SD. *P<0.05 vs UT. siRNA, short interfering RNA; siRNAscr, scrambled siRNA; UT, untransfected; MLVD, microlymphatic vessel density.